LLY shares edge lower amid overbought signals on Bull/Bear Power indicator: weekly report

Traders Union
All News
Financial News
Eli Lilly falls 4.15% this week

Highlights

LLY maintains a strong medium- and long-term uptrend, trading well above key moving averages despite short-term pressure.
Recent 4.15% decline places LLY at the week's low, suggesting current consolidation amid high weekly volatility of 7.82%.
Price is expected to consolidate between $1,070 and $1,210, with technical signals indicating an 80%+ probability of an upward move.

Expanded FDA approval and mixed investor moves shape weekly sentiment

Eli Lilly's drug selpercatinib (Retevmo) received full FDA approval for treating solid tumors with RET gene fusions, expanding options for adult and pediatric patients and strengthening the oncology portfolio. Several institutional investors adjusted their holdings in LLY, with some increasing and others reducing their positions. The company continues to face regulatory and operational challenges related to drug pricing and manufacturing scalability.

Momentum indicators diverge as LLY consolidates above key averages this week

Technical analysis on the weekly timeframe shows LLY firmly above all major moving averages, with the MA-50 providing dynamic support. Last week’s close near the lower end of the range indicates persistent downward momentum despite a supportive medium-term trend. Weekly volatility is elevated at 7.82%. Momentum indicators such as MACD and ADX are in Buy mode, while weekly RSI remains bullish and CCI is positive, reflecting underlying strength. Nonetheless, Bull/Bear Power reveals an overbought environment, hinting at short-term exhaustion. Most oscillators have turned neutral or mixed, and the Awesome Oscillator remains flat, suggesting consolidation after recent declines. Key support is seen near $1,070, with initial resistance at $1,210.

Sideways trading expected as breakout risk hinges on volatility

Looking ahead, LLY is expected to trade between $1,070 and $1,210 over the next five trading days, with a strong likelihood (over 80%) of an upward move supported by consistent Buy signals from weekly RSI, ADX, MACD, and CCI. The baseline scenario points to consolidation in this sideways corridor as volatility persists. Should momentum resume and LLY move above $1,210, a breakout towards new highs is feasible. Alternatively, a sustained drop below $1,070 could trigger further downside before stabilization.

Anton Kharitonov, analyst at Traders Union, notes that Eli Lilly stayed well above major weekly averages this week but lost ground toward the bottom of its recent range. He sees momentum indicators still flashing Buy signals, but points out overbought conditions and mixed oscillator readings that limit upside confidence. Institutional position shifts and recent full FDA approval for selpercatinib reflect fundamental strength, yet operational and regulatory challenges remain. Volatility is high and the technical environment now suggests sideways movement between $1,070 and $1,210. Kharitonov believes that while upward moves are statistically favored, the market faces clear exhaustion near current highs. "Base case is consolidation with a slight upward bias, but unless LLY clears $1,210, I stay cautious this week."

Earlier, analysts noted that Eli Lilly was experiencing short-term price weakness despite robust longer-term trends and ongoing product milestones. Building on this, the latest developments in FDA approvals and strong technical support reinforce Eli Lilly’s upward bias, with a decisive move above $1,210 likely signaling a breakout toward new highs if recent consolidation resolves to the upside.

Source of Data: LLY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.